×

What are you searching for?




Healthcare

4 Min read

Quiet Period To End on November 20th Vir Biotechnology’s (NYSE: VIR)

Published On 12 Dec 2019 11:20 AM


SHARE THIS ARTICLE  


Several analysts have written on the stock recently. In a research report on Tuesday, November 5, Barclays assumed reporting on Vir Biotechnology stock. We set a stock "overweight" score and a price target of $25.00. In a research report on Wednesday, November 13, Robert W. Baird assumed coverage of Vir Biotechnology shares. They set on stock a "neutral" rating. In a research report on Tuesday, November 5, JPMorgan Chase &a....


Tags : Barclays, ,
SHARE THIS ARTICLE  

Leave a comment 

comments (0)